Company Overview
XTL Biopharmaceuticals Ltd., identified by the ticker XTLB, operates as a biopharmaceutical entity focused on the acquisition and development of pharmaceutical drugs designed for the treatment of autoimmune diseases within Israel. The company's strategic lead asset is hCDR1, a Phase II-ready candidate specifically engineered to address systemic lupus erythematosus and Sjogren's syndrome. This firm functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to leverage advancements in biologic therapies for chronic immune-mediated conditions. XTLB currently demonstrates a small operational scale, with a market capitalization of $5.94 million, annual revenue of $968,000, and an employee count of 10. The combination of a sub-$10 million market cap and revenue under one million dollars indicates that the company remains in an early-stage development phase, relying heavily on asset acquisition and research rather than established commercial sales volume.
Financial Health
The company reported trailing twelve-month revenue of $968,000 against a net income of -$6,308,000, while EBITDA figures are not available for reporting. The substantial disparity between the modest revenue figure and the significant negative net income reveals a cost structure dominated by research and development expenses that far exceed current sales generation. Regarding cash flow dynamics, free cash flow data is not disclosed, which precludes an immediate assessment of operational cash generation efficiency in the current period. The financial margins present a complex picture: the gross margin stands at -232.9%, the operating margin at -853.6%, and the profit margin at 0.0%. These negative or zero margin percentages reflect the typical economic profile of a pre-revenue biotechnology firm where fixed R&D costs create losses that are not offset by product sales revenue. On the balance sheet, the company holds $259,000 in cash against $86,000 in debt, though a specific debt-to-equity ratio is not calculated or provided. While the cash position exceeds debt obligations, the absence of an explicit debt-to-equity metric limits the ability to quantify leverage relative to shareholder equity. The current ratio is recorded at 0.70, indicating that the company's current assets are less than its current liabilities, which suggests a constrained short-term liquidity position typical for capital-intensive biotech ventures. Return on Equity is reported at -577.1% and Return on Assets at -240.6%, metrics that mathematically reflect the dilution of shareholder value and asset efficiency caused by the net losses incurred during the development lifecycle.
Valuation Assessment
Trailing twelve-month P/E ratio and forward P/E ratio data are not available for XTLB, a standard characteristic for companies that have not yet achieved profitability. The absence of a trailing P/E ratio implies that valuation cannot be anchored to current earnings per share, while the lack of a forward P/E suggests that analyst consensus on future normalized earnings has not yet materialized. The price-to-book ratio is not available, preventing a direct comparison of the market's valuation of the company against its net asset book value. Instead, alternative valuation metrics are utilized; the price-to-sales ratio stands at 6.13, and the EV/EBITDA ratio is not available. A price-to-sales multiple of 6.13 indicates that the market is pricing the company based on its top-line revenue potential rather than earnings power, reflecting the high-risk, high-reward nature of early-stage biotech assets. The stock has traded between a 52-week high of $2.64 and a 52-week low of $0.53. Without a specific current price listed in the provided facts, the exact percentage distance from these bounds cannot be calculated, but the wide range illustrates significant price volatility inherent in small-cap biotechnology stocks. The beta is 0.73, which indicates that the stock's price volatility is lower than the broader market benchmark, suggesting it may be less sensitive to general market fluctuations despite its small market capitalization.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year figures are not available in the current dataset, likely due to the short operating history or the nature of the company's revenue recognition. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue, as both growth rates are currently unquantifiable. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%. This zero payout ratio is consistent with the company's status as a non-dividend payer, meaning that any generated earnings or retained capital are theoretically reinvested into growth initiatives such as clinical trials or drug development rather than distributed to shareholders. Since the company does not distribute income to investors, its growth profile is entirely dependent on the successful advancement of its pipeline assets and the eventual commercialization of hCDR1. The overall growth and income profile for XTLB is characterized by a lack of historical growth data and an absence of dividend income, positioning the investment thesis strictly on potential future value creation from pipeline milestones rather than current cash returns.